. Author manuscript; available in PMC: 2013 May 1.

Published in final edited form as: Clin Microbiol Infect. 2012 Mar 8;18(5):E122–E127. doi: 10.1111/j.1469-0691.2012.03777.x

Table 2.

Clinical outcomes in patients with invasive aspergillosis at 6 and 12 weeks.

	6 weeks	12 weeks
All IA patients (n = 88)
All-cause mortality (95% CI)^a	0.51 (0.41, 0.62)	0.60 (0.50, 0.70)
Clinical failure in response to antifungal therapy (95% CI)^a,^b	0.64 (0.54, 0.74)^c	0.62 (0.52, 0.72)^d
Patients with ≥2 BG values (n = 69)
All-cause mortality (95% CI)^a	0.38 (0.27, 0.50)	0.49 (0.38, 0.62)
Clinical failure in response to antifungal therapy (95% CI)^a,^b	0.54 (0.42, 0.66)	0.51 (0.40, 0.63)

95% CI: 95% confidence interval

As defined by 2008 EORTC/MSG consensus criteria for defining responses to antifungal therapy

At 6 weeks, 32 patients were considered clinical ‘successes’ (3 complete clinical responses, 29 partial responses) and 56 were considered clinical ‘failures’ (6 stable responses, 5 progressive disease, and 45 deaths).

At 12 weeks, 34 patients were considered clinical ‘successes’ (13 complete clinical responses, 21 partial responses) and 54 were considered clinical ‘failures’ (0 stable responses, 2 progressive disease, 52 deaths).